Clinical Trials Sponsored by Dongguan HEC Biopharmaceutical R&D Co., Ltd.

Total 7 results

Dongguan HEC Biopharmaceutical R&D Co., Ltd.

Completed

The Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy Subjects

Non-alcoholic Steatohepatitis

Australia
Dongguan HEC Biopharmaceutical R&D Co., Ltd.

Completed

A Phase 1 Study of HEC88473 Injection in Healthy Subjects, Obese Subjects and T2DM Subjects

Obesity | Healthy Subjects | T2DM (Type 2 Diabetes Mellitus)

China
Dongguan HEC Biopharmaceutical R&D Co., Ltd.

Recruiting

Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes

China
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.

Completed

A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients

Cirrhosis | Chronic Hepatics C Virus (HCV) Genotype 1 | Non-Cirrhotic | Treatment naïve

China
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
R&G Pharma Studies Co.,Ltd.

Completed

To Evaluate the Safety, Tolerability, and Pharmacokinetics Profile in Healthy Chinese Volunteers of TG-2349

Healthy Chinese Volunteers

China
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
R&G Pharma Studies Co.,Ltd.

Completed

To Evaluate PK and Safety Profile of Oral MAD of Separately Using TG-2349, DAG181 or Combination in Healthy Chinese Volunteers

Healthy Chinese Volunteers

China
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
Peking University People's Hospital

Completed

To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients

Cirrhosis | Chronic Hepatics C Virus (HCV) Genotype 1 | Non-Cirrhotic | Treatment naïve

China

Clinical Trials Sponsored by Dongguan HEC Biopharmaceutical R&D Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations